Resource And Cost Savings Due To Subcutaneous Versus Intravenous Administration Of Oncology Therapies- Case Studies With Rituximab (Mabthera) And Trastuzumab (Herceptin)
Abstract
Authors
S Walzer S Era A Profico M Canciani M Farina C Ponzetti